Clinical Trials in Baltimore

Showing 3481-3500 of 11,213 trials

Glyburide Advantage in Malignant Edema and Stroke Pilot

NCT01268683

The primary objective of this study is to assess the feasibility of enrolling, evaluating, and treating with glyburide for injection severe anterior circulation ischemic stroke participants, whether or not treated with standard of care intravenous (IV) recombinant tissue plasminogen activator (rtPA). Participants must be between 18-80 years of age, must have a baseline diffusion weighted image (DWI) lesion volume 82 -210 centimeters cubed (cm3), and time from symptom onset to start of study infusion must be ≤10 hour(hr). The secondary objectives are to assess the initial safety and tolerability, and pharmacokinetics (PK) /pharmacodynamics (PD) of glyburide in severe stroke participants, as well as to compare the clinical and magnetic resonance imaging (MRI) outcome data to benchmark data derived from published literature.

Ischemic Stroke

Remedy Pharmaceuticals, Inc.10 participantsStarted May 2011

Chicago, Illinois, United States • Baltimore, Maryland, United States • Boston, Massachusetts, United States +1 more locations

TERMINATEDPhase 1< 1 mile

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

NCT05824559

This is a Phase 1b open-label, multiple dose/schedule sequential study to determine the safety and efficacy of the oxidative phosphorylation (OxPhos) pathway inhibitor ME-344 in combination with bevacizumab in subjects with recurrent mCRC.

Colorectal Cancer

MEI Pharma, Inc.23 participantsStarted Aug 2023

Los Angeles, California, United States • Miami Beach, Florida, United States • Baltimore, Maryland, United States +4 more locations

Glyburide Advantage in Malignant Edema and Stroke Pilot

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Find Trials by Condition in Baltimore

The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

ReadMap: Reading in Stroke Alexia and Typical Aging

A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Promoting Independence With Compensatory Cognitive Rehabilitation

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC